Krsnaa Diagnostics Limited · NSE:KRSNAA
Krsnaa Diagnostics — Q3 FY2025 Earnings Presentation
19 slides from Krsnaa Diagnostics's earnings presentation, Feb 12, 2025
Slide 1: Regulation 30 intimation letter to stock exchanges
Date: February 12, 2025 Ref. No.: KDL/SE/131/2024-25 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 4
Slide 2: Q3FY2025 Result Presentation
Q3FY2025 Result Presentation One of INDIA’S LARGEST Differentiated Diagnostic Service Provider February 2025
Slide 3: Q3FY2025 & 9MFY25 Performance
Q3FY2025 & 9MFY25 Performance
Slide 4: Krsnaa Diagnostics Q3FY25 Operations at a Glance
Krsnaa Krsnaa Diagnostics Diagnostics Q3FY25At Operations- – aOperations Glance at a Glance Radiology Pathology India's 1st India’s 1st CAP Accreditation NABH Accredited Tele 178 in Govt. Hospital radiology HUB 121 CT/MRI Centres Processing lab 1,434 NABH NABL 3,423 Tele-Reporting Collection Centre
Slide 5: Krsnaa Diagnostics 9MFY25 Financials at a Glance
Krsnaa Krsnaa Diagnostics Diagnostics 9MFY25 Financial- At a– Glance Financials at a Glance In mn Sustained Growth: Achieving 17% YoY Revenue Growth, 39% YoY EBITDA Strengthening & 49% YoY improvement in PAT, on account of improved footfalls across our centers and enhanced operational efficiency Rev
Slide 6: Krsnaa Diagnostics Q3FY25 Financials at a Glance
Krsnaa Diagnostics Q3FY25 – Financials at a Glance In mn Sustained Growth: Achieving 10% YoY Revenue Growth, 23% YoY EBITDA Strengthening & 50% YoY improvement in PAT on account of improved footfalls across our centers and enhanced operational efficiency Revenue from operation EBIDTA PAT Q3FY25 1,74
Slide 7: 9MFY25 Financial Performance: EBITDA Analysis
9MFY25 –Performance Financial EBIDTA Analysis In mn 9M EBIDTA Centre wise EBIDTA Bifurcation Existing Centre New Centre 27% 2,588 23% c 2,723 447 969 9MFY24 9MFY25 Revenue EBIDTA EBIDTA BRIDGE 3% 27% 2% 23% -1% c Note: Considering the nature of 9MFY24 Network Addition Employee Addition Operational E
Slide 8: Key Developments
—@® Key Developments
Slide 9: Key Company Developments
KeyCompany Only Developments with Pan India Presence in Both Radiology and Pathology KRSNAA Expanded our Entering the Retail Honored with the Presence by Diagnostics Space Leading HR Establishing 284 Transformation Additional Collection Award Centers Across the Nation 12 Labs Received Successfully A
Slide 10: Embarking on Retail Journey, Integrated Diagnostics, B2B Collaboration
Embarking Only Company on withRetail Journey Pan India Presence in Both Radiology and Pathology Krsnaa Retail Network Integrated Diagnostics • Current presence of 80 KBAs • Leveraging existing infrastructure for Radiology & Pathology both for better patient care • Target to expand retail network to
Slide 11: Pan India Presence in Both Radiology and Pathology
PANCompany Only India Presence in Radiology with Pan India Presence in&Both Pathology Radiology and Pathology Well Diversified Regional Revenue Mix 14% 31% Q3FY2025 36% 19% West South North East ▪ Highest penetration across districts with presence in 150+ out of 700+ districts; still large underpene
Slide 12: Projects Under Implementation
Project Only Under Company Implementation with Pan India Presence in Both Radiology and Pathology Radiology Centres Under Implementation Pathology Centres Under Implementation Total Centres Operational Under Total Centres Operational Under Implementation Implementation Uttar Pradesh 8 5 3 BMC CC 600
Slide 13: Enhancing Visibility and Awareness
Enhancing Enhancing Visibility Visibility and Awareness and Awareness IN-SHOP BRANDING PROMOTIONAL BRANDING HEALTH CHECKUP CAMP/AWARENESS COCO CENTRE 10
Slide 14: Awards and Accolades
Awards and Enhancing Accolades Visibility and Awareness Best Diagnostic Leading HR Lab Chain of the Transformation year (West) Award 11
Slide 15: Growth Strategy
Growth Only Strategy Company with Pan India Presence in Both Radiology and Pathology We aim to sustain the upward trajectory of our Revenue and PAT CAGR by utilizing our existing facilities and seizing opportunities in untapped markets Tap the growing and Continue to enhance Building the Retail Digi
Slide 16: Krsnaa Diagnostics Edge
Krsnaa Only Diagnostics Company Edge with Pan India Presence in Both Radiology and Pathology ₹ Extensive Strong Scalable & Agile Cost Stakeholder Geographic Brand Equity Business Model Leadership Value Footprint Creation Centres across India with Well positioned to PPP is an asset light Ability to m
Slide 17: Financial Performance
—@® Financial Performance
Slide 18: Financial Performance
Financial Only Performance Company with Pan India Presence in Both Radiology and Pathology In mn Particulars Q3 FY 25 Q3 FY 24 Q2 FY 25 9M FY 25 9M FY 24 Amount % Amount % Amount % Amount % Amount % Revenue from operations 1,745 1,583 1,863 5,311 4,534 Expenses Cost of Material Consumed 399 23% 344
Slide 19: Contact Information
Contact Contact Information Information This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments